Применение прамипексола при болезни Паркинсона

1. Голубев В.Л., Левин Я.И., Вейн А.М. Болезнь Паркинсона и синдром паркинсонизма. М.: МЕДпресс, 1999.
2. Левин О.С. Клинико-нейропсихологические и нейровизуализационные аспекты дифференциальной диагностики паркинсонизма. Автореф. дис. ... д-ра. мед. наук. М., 2003.
3. Левин О.С. Лечение болезни Паркинсона на ранней стадии. В мире лекарств. 2001; 1: 41–7.
4. Левин О.С. Развитие моторных флуктуаций у больных с различными стадиями болезни Паркинсона. Атмосфера. Нервные болезни 2005; 1: 10–6.
5. Левин О.С., Федорова Н.В., Смоленцева И.Г. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. Рус. мед. журн. 2000; 15–16: 643–46.
6. Левин О.С., Смоленцева И.Г., Наймушина Т.В. Психотические расстройства при болезни Паркинсона: клинико-нейропсихологическое исследование. Неврологич. журн. 2002; 5: 21–8.
7. Левин О.С., Смоленцева И.Г., Цередсодном Б. и др. Влияние дофаминергической терапии на нейропсихологические функции у больных болезнью Паркинсона. Неврологич. журн. 2004; 3: 31–7.
8. Левин О.С., Федорова Н.В. Болезнь Паркинсона. М., 2006.
9. Левин О.С., Смоленцева И.Г., Цэрэнсодном Б. Эффективность прамипексо-
ла при болезни Паркинсона (по данным открытого 12-месячного исследования). Фарматека. 2007; 1: 28–34.
10. Протокол ведения больных. Болезнь Паркинсона. Пробл. стандартизац. в здравоохр. 2005; 3: 74–166.
11. Смоленцева И.Г. Влияние агонистов дофаминовых рецепторов на двигательные и нейропсихологические нарушения при болезни Паркинсона. Дис.... канд. мед. наук. М., 2000.
12. Яхно Н.Н., Нодель М.Р., Федорова Н.В. и др. Эффективность и переносимость прамипексола при продолжительной терапии у пациентов с болезнью Паркинсона. Неврологич. журн. 2004; 3: 25–30.
13. Almeda S., Ranjith G. Using pramipexole in neuropsychiatry: a cautionary note. J Neuropsychiatry Clin Neurosci 2006; 18: 556–7.
14. Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson disease. J Neurol 2006; 253: 555–61.
15. Biglan KM, Holloway RH, McDermott MP et al. Risk factors for somnolence, edema and hallucinations in early Parkinson disease. Neurology 2007; 69: 187–95.
16. Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry, 2000; 68: 685–9.
17. Brusa L, Bassi A, Stefani A et al. Pramipexole in comparison to L-dopa: a neuropsychological study. J Neural Transm 2003; 110; 373–80.
18. Constantinescu R, Romer M, McDermott MP et al. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007; 22: 1317–9.
19. DeBattista C, Solvason HB, Breen J et al. Pramipexole in the augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol 2000; 20: 274–5.
20. Fishman PS. Paradoxical aspects of parkinsonian tremor. Mov Disord 2008; 23: 168–73.
21. Guttman M. and the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49: 1060–5.
22. Hauser RA, McDermott MP, Messing S et al. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006; 63: 1756–60.
23. Hauser RA, Rascol O, Korczyn AD et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22: 1458–63.
24. Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment
for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol
2004; 61: 1044–53.
25. Hubble JP, Koller WC, Cutler NR et al. Pramipexole in patients with early Parkinson's
disease. Clin Neuropharmacol 1995; 18: 338–47.
26. Inzelberg R, Carasso RL, Schechtman E et al. A comparison of dopamine agonists
and catechol-O-methyltransferase inhibitors in Parkinson's disease. Clin Neuropharmacol
2000; 23: 262–6.
27. Kleiner-Fisman G, Fisman D. Risk factors for the development of pedal edema in
patients using pramipexole. Arch Neurol 2007; 64: 820–4.
28. Lemke MR, Brecht HM, Koester J et al. Anhedonia, depression and motor functioning
in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry
Clin Neurosci 2005; 17: 214–20.
29. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in
advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-
group study. Neurology 1997; 49: 162.
30. Marras C, Lang A, Krahn M et al. Quality of life in early Parkinson's disease:
impact of dyskinesias and motor fluctuations. Mov Disord 2004; 19: 22–8.
31. Moller JC, Oertel WH, Koster J et al. Long-term efficacy and safety of pramipexole
in advanced Parkinson's disease: results from a European multicenter trial. Mov
Disord 2005; 20: 602–10.
32. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for
Parkinson's disease. A randomized controlled trial. JAMA 2000; 284: 1931–8.
33. Parkinson Study Group. Dopamine transporter brain imaging to assess the
effects on pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;
287: 1653–61.
34. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline
dopamine agonist pramipexole in the treatment of advanced Parkinson's disease:
a double blind, placebo controlled, randomised, multicentre study. J Neurol
Neurosurg Psychiatry 1999; 66: 436–41.
35. Pogarell O, Gasser T, van Hilten JJ et al. Pramipexole in patients with Parkinson's
disease and marked drug resistant tremor: a randomised, double blind,
placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72:
713–20.
36. Poewe W, Rascol O, Quinn N et al. Efficacy of pramipexole and transdermal
rotigotine in advanced Parkinson's disease. Lancet Neurology 2007; 6: 513–20.
37. Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment
of depression in Parkinson disease. Eur J Neurol 2003; 10: 399–406.
38. Reichmann H, Odin P, Brecht HM et al. Changing dopamine agonist treatment
in Parkinson disease. J Neural Transm 2006; 71: 17–25.
39. Schapira AH. Treatment options in the modern management of Parkinson disease.
Arch Neurol 2007; 64: 1083–8.
40. Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel
dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology
1997; 49: 724–8.
41. Shulman LM, Minagar A, Rabinstein A et al. The use of dopamine agonists in
very elderly patients with Parkinson's disease. Mov Disord 2000; 15: 664–8.